Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly.

Emanuele VaraldoN PrencipeC BonaD CuboniL S AversaM SibillaF BiolettoA M BertonC GramagliaV GascoE GhigoS Grottoli

Published in: Journal of endocrinological investigation (2024)

Our results confirm the efficacy of CAB in providing a significant improvement in the biochemical disease control but do not demonstrate a marked benefit on glucose metabolism of acromegaly patients. In such patients, CAB appears to have a rapid effect on weight and BMI, with significant changes noticeable as early as 6 months and persisting for at least 12 months.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
body mass index
prognostic factors
patient reported
quantum dots